Telavancin

立即咨询

Telavancin

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

372151-71-8

TD-6424

Telavancin (TD-6424) 是一种半合成的脂糖肽万古霉素衍生物，是一种新型抗菌剂，用于克服耐药革兰氏阳性细菌感染，特别是耐甲氧西林金黄色葡萄球菌 (MRSA)。Telavancin 能够破坏细胞膜完整性，可用于革兰氏阳性菌引起的复杂皮肤和皮肤结构感染 (cSSSIs) 的研究。

生物活性

Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positivebacterialinfections, specifically methicillin-resistantStaphylococcus aureus(MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria^[1].

IC₅₀& Target

Glycopeptide

体外研究
(In Vitro)

Telavancin has a rapid, concentration-dependent bactericidal effect, due to disruption of cell membrane integrity^[1].
Telavancin (5 μg/mL) exerts bacteriocidal effect against a MRSA strain (COL) and a VISA strain (HIP5836) at a concentration of 5 μg/mL^[1].

体内研究
(In Vivo)

Telavancin has been tested in various relevant animal models of infection, namely, bacteremia (40 mg/kg/d; s.c.; twice a day, with 12 h space), endocarditis (30 mg/kg/d; i.v.; twice a day, with 12 h space; 4 d), meningitis, and pneumonia with success^[1]

Animal Model:	MRSA bacteremia model in neutropenic mice^[1]
Dosage:	40 mg/kg
Administration:	Subcutaneous injection; twice every day spaced 12 h apart
Result:	Resulted a significantly higher 14-day survival compared with vancomycin-treated animals.

Animal Model:	Rabbit model ofS. aureusendocarditis^[1]
Dosage:	30 mg/kg
Administration:	Intravenous injection; twice every day, spaced 12 h for 4 days
Result:	Significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture negative.

Clinical Trial

分子量

1755.63

Formula

C₈₀H₁₀₆Cl₂N₁₁O₂₇P

CAS 号

372151-71-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.